Toronto Dominion Bank
TVTX icon

Toronto Dominion Bank’s Travere Therapeutics TVTX Stock Holding History

Toronto Dominion Bank’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3
Closed -$115 – 2408
2025
Q4 		$115 Hold
3
– – ﹤0.01% 2019
2025
Q3 		$72 Hold
3
– – ﹤0.01% 1883
2025
Q2 		$44 Hold
3
– – ﹤0.01% 1766
2025
Q1 		$54 Buy
+3
New +$61 ﹤0.01% 1515
2024
Q3 		– Sell
-3
Closed -$25 – 1435
2024
Q2 		$25 Hold
3
– – ﹤0.01% 1411
2024
Q1 		$23 Hold
3
– – ﹤0.01% 1387
2023
Q4 		$27 Hold
3
– – ﹤0.01% 1536
2023
Q3 		$27 Hold
3
– – ﹤0.01% 1775
2023
Q2 		$0 Hold
3
– – ﹤0.01% 1794
2023
Q1 		$0 Buy
+3
New +$64 ﹤0.01% 1712
2022
Q3 		– Sell
-48
Closed -$1K – 1713
2022
Q2 		$1K Buy
+48
New +$1.21K ﹤0.01% 1261
2022
Q1 		– Sell
-78,942
Closed -$2.45M – 1992
2021
Q4 		$2.45M Buy
+78,942
New +$2.22M ﹤0.01% 783

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Toronto Dominion Bank's TVTX Position: Q1 2026 in Review

Toronto Dominion Bank sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 3 shares — an estimated $115 sold.

Toronto Dominion Bank first reported a position in TVTX in Q4 2021 and held it in 12 quarters. The position peaked at $2.45M in Q4 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Toronto Dominion Bank reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Toronto Dominion Bank sold 3 Travere Therapeutics shares in Q1 2026, an estimated $115.
  • Toronto Dominion Bank first reported a position in Travere Therapeutics in Q4 2021 and held it in 12 quarters.
  • Toronto Dominion Bank's Travere Therapeutics position peaked at $2.45M in Q4 2021.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Toronto Dominion Bank's 13F filing for Q1 2026, filed 15 May 2026.